Resources

TAXIS Pharmaceuticals has named two industry professionals with extensive biopharma experience, Joeseph DePinto, MBA, and Frank Carlo Pasqualone, MBA, to its Board of Directors.

A conversation with Gregory G. Mario and Ajit K. Parhi, Ph.D., TAXIS Pharmaceuticals originally published in Drug Discovery Online.

TAXIS has received a $2.9 million grant to further advance R&D efforts for its dihydrofolate reductase inhibitors (DHFRIs) as a novel approach to combat multi-drug resistant gonorrhea, a rapidly spreading deadly and highly resistant strain of Neisseria gonorrhoeae.

Understanding the mechanisms behind antibiotic resistance reveals the pressing need for innovative solutions in the pharmaceutical landscape. Presenting TAXIS Pharmaceuticals' Commitment to Innovation: TXA709. TAXIS is dedicated to developing novel therapies that specifically target resistant strains of bacteria.

Our new white paper delves into the global scope of AMR, shedding light on its widespread impact and the variability of its effects across different regions. The paper outlines actionable strategies to combat AMR, such as enhancing global surveillance systems, advocating for responsible antibiotic use, investing in the development of innovative treatments, and fostering international collaboration.

The prospective bill, the Pasteur Act, is one potential strategy to help in these areas, and incentivize pharmaceutical companies to develop these essential therapies. This article was originally published on contagionlive.com.  

This article was originally published in Genetic Engineering & Biotechnology News under the title of The Antimicrobial Resistance Crisis Eradicating a Global Health Threat

Reversing the Rapid Rise of Antibiotic Resistance. Greg Mario joins David E. Williams to discuss the real and potentially imminent dangers of antibiotic-resistant infections and the new technologies being developed to combat this growing threat.

Antimicrobial resistance (AMR) is not a new phenomenon; it has been a persistent challenge since the discovery of antibiotics. TAXIS Pharmaceuticals is at the forefront of addressing antimicrobial resistance, developing innovative antimicrobial solutions.